Status:
COMPLETED
Exploratory Study of Breast Cancer With ABY025
Lead Sponsor:
Biomedical Radiation Sciences
Collaborating Sponsors:
Swedish Cancer Society
Conditions:
Breast Cancer
Eligibility:
FEMALE
20+ years
Phase:
PHASE1
PHASE2
Brief Summary
The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.
Eligibility Criteria
Inclusion
- female age \>20 years
- one or more known metastases localizations
Exclusion
- other critical disease than breast cancer
- age ≤ 20 years
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01216033
Start Date
October 1 2010
End Date
July 1 2011
Last Update
April 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akademiska Hospital
Uppsala, Uppland, Sweden, SE75185